Behavior-selective apoptotic capacity of 4-(3,4,5-trimethoxyphenoxy) benzoic acid and its methyl derivatives on two breast cancer cell lines

Anticancer Research

Volumn 34, Issue 4, 2014, Pages 1801-1810

  Lee, Kuan Han ^a   Ho, Wen Yueh ^a   Wu, Shu Jing ^a   Cheng, Tsung Lin ^b   Huang, Po Jui ^c   Wang, Clay C C ^d   Hung, Jui Hsiang ^a  

^a CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Apoptosis; Breast cancer; Caspase 3; Colony formation; MCF 7; MDA 468

Indexed keywords

4 (3,4,5 TRIMETHOXYPHENOXY) BENZOIC ACID; ANTINEOPLASTIC AGENT; BENZOIC ACID DERIVATIVE; CASPASE 3; UNCLASSIFIED DRUG; BENZOIC ACID;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER INHIBITION; CANCER THERAPY; CELL DEATH; CELL PROLIFERATION; CELL STRUCTURE; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME ACTIVITY; FEMALE; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; HELA CELL LINE; HEPG2 CELL LINE; HUH 7 CELL LINE; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; MCF 7 CELL LINE; MDA MB 468 CELL LINE; MINIMUM INHIBITORY CONCENTRATION; MTT ASSAY; TREATMENT RESPONSE; BREAST TUMOR; CELL CYCLE; CELL SURVIVAL; CHEMISTRY; DRUG EFFECT; DRUG SCREENING; IC 50; MCF-7; MDA-468; TUMOR CELL LINE;

APOPTOSIS; BREAST CANCER; CASPASE-3; COLONY FORMATION; MCF-7; MDA-468;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZOIC ACID; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; MCF-7 CELLS; TUMOR STEM CELL ASSAY;

EID: 84902279372     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Bray F, Sankila R, Ferlay J and Parkin DM: Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer 38: 99-166, 2002.
2. Mettlin C: Global breast cancer mortality statistics. CA Cancer J Clin 49: 138-144, 1999.
3. Nelson HD, Zakher B, Cantor A, Fu R, Griffin J, O'Meara ES, Buist DS, Kerlikowske K, van Ravesteyn NT, Trentham-Dietz A, Mandelblatt JS and Miglioretti DL: Risk factors for breast cancer for women aged 40 to 49 years: A systematic review and meta-analysis. Ann Intern Med 156: 635-648, 2012.
4. Peshkin BN, Alabek ML and Isaacs C: BRCA1/2 mutations and triple negative breast cancers. Breast Dis 32: 25-33, 2010.
5. Kröger N, Milde-Langosch K, Riethdorf S, Schmoor C, Schumacher M, Zander AR and Löning T: Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients. Clin Cancer Res 12: 159-68, 2006.
6. Wu AH, Pike MC, Williams LD, Spicer D, Tseng CC, Churchwell MI and Doerge DR: Tamoxifen, soy, and lifestyle factors in Asian American women with breast cancer. J Clin Oncol 25: 3024-3030, 2007.
7. Niraula S, Ocana A, Ennis M and Goodwin PJ: Body size and breast cancer prognosis in relation to hormone receptor and menopausal status: A meta-analysis. Breast Cancer Res Treat 134: 769-781, 2012.
8. Newcomb PA, Kampman E, Trentham-Dietz A, Egan KM, Titus LJ, Baron JA, Hampton JM, Passarelli MN and Willett WC: Alcohol consumption before and after breast cancer diagnosis: Associations with survival from breast cancer, cardiovascular disease, and other causes. J Clin Oncol 31: 1939-1946, 2013.
9. Behr TM, Béhé M and Wörmann B: Trastuzumab and breast cancer. N Engl J Med 345: 995-996, 2001.
10. van Dalsen AD and de Vries JE: Treatment of breast cancer in elderly patients. J Surg Oncol 60: 80-82, 1995.
11. Schechter AL, Stern DF, Vaidyanathan L, Decker SJ, Drebin JA, Greene MI and Weinberg RA: The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 312: 513-516, 1984.
12. Robertson KW, Reeves JR, Smith G, Keith WN, Ozanne BW, Cooke TG and Stanton PD: Quantitative estimation of epidermal growth factor receptor and c-erbB-2 in human breast cancer. Cancer Res 56: 3823-3830, 1996.
13. Wu Y, Amonkar MM, Sherrill BH, O'Shaughnessy J, Ellis C, Baselga J, Blackwell KL and Burstein HJ: Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer. Ann Oncol 22: 2582-2590, 2011.
14. Nahta R, Hung MC and Esteva FJ: The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 64: 2343-2346, 2004.
15. Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, Sahmoud T; ATAC Trialists' Group: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359: 2131-2139, 2002.
16. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS; ATAC Trialists' Group: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365: 60-62, 2005.
17. Yu D, Liu B, Tan M, Li J, Wang SS and Hung MC: Overexpression of c-ERBB-2/neu in breast cancer cells confers increased resistance to Taxol via MDR-1-independent mechanisms. Oncogene 13: 1359-1365, 1996.
18. Suter TM, Procter M, van Veldhuisen DJ, Muscholl M, Bergh J, Carlomagno C, Perren T, Passalacqua R, Bighin C, Klijn JG, Ageev FT, Hitre E, Groetz J, Iwata H,Knap M, Gnant M, Muehlbauer S, Spence A, Gelber RD and Piccart-Gebhart MJ: Trastuzumab-associated cardiac adverse effects in the Herceptin adjuvant trial. J Clin Oncol 25: 3859-3865, 2007.
19. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63: 11-30, 2013.
20. Jänicke RU, Sprengart ML, Wati MR and Porter AG: Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem 273: 9357-9360, 1998.
21. Porter AG, Jänicke RU: Emerging roles of caspase-3 in apoptosis. Cell Death Differ 6: 99-104, 1999.
22. Huang HJ, Neven P, Drijkoningen M, Paridaens R, Wildiers H, Van Limbergen E, Berteloot P, Amant F, Vergote I and Christiaens MR: Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer. J Clin Pathol 58: 611-616, 2005.
23. Lal P, Tan LK and Chen B: Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas. Am J Clin Pathol 123: 541-546, 2005.